• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性淋巴细胞白血病细胞中的B细胞受体信号传导由过度表达的活性蛋白激酶CβII调节。

B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.

作者信息

Abrams Simon T, Lakum Tasneem, Lin Ke, Jones Gemma M, Treweeke Andrew T, Farahani Mosavar, Hughes Mair, Zuzel Mirko, Slupsky Joseph R

机构信息

Department of Haematology, University of Liverpool, UK.

出版信息

Blood. 2007 Feb 1;109(3):1193-201. doi: 10.1182/blood-2006-03-012021. Epub 2006 Sep 26.

DOI:10.1182/blood-2006-03-012021
PMID:17003377
Abstract

Signals through the B-cell antigen receptor (BCR) are important for the survival of chronic lymphocytic leukemia (CLL) cells. Therefore, factors that influence these signals have important pathophysiological roles in this disease. One key mediator of BCR signaling is protein kinase C beta (PKCbeta), which regulates the activation of I-kappaB kinases and the deactivation of Bruton tyrosine kinase within the signaling pathways initiated by BCR engagement. The present study demonstrates that overexpression of the PKCbetaII isoform is a feature of CLL cells and that activity of this enzyme strongly correlates with CLL cell response to BCR engagement. Thus, intracellular Ca2+ release and increases in cell survival after BCR cross-linking were significantly greater in CLL patients with low levels than in CLL patients with high levels of active PKCbetaII. Furthermore, BCR-induced Ca2+ fluxes could be restored in CLL patients with high levels of active PKCbetaII by pretreating the cells with the PKCbeta-specific inhibitor LY379196. Conversely, BCR-mediated intracellular Ca2+ release could be inhibited in CLL cells with low levels of active PKCbetaII by pretreatment with the PKC agonist bryostatin. Taken together, these results demonstrate that overexpressed active PKCbetaII plays a role in the regulation and outcome of BCR signals that can be important for the progression of CLL.

摘要

通过B细胞抗原受体(BCR)传导的信号对于慢性淋巴细胞白血病(CLL)细胞的存活至关重要。因此,影响这些信号的因素在该疾病中具有重要的病理生理作用。BCR信号传导的一个关键介质是蛋白激酶Cβ(PKCβ),它在由BCR结合引发的信号通路中调节I-κB激酶的激活和布鲁顿酪氨酸激酶的失活。本研究表明,PKCβII亚型的过表达是CLL细胞的一个特征,并且该酶的活性与CLL细胞对BCR结合的反应密切相关。因此,活性PKCβII水平低的CLL患者在BCR交联后细胞内Ca2+释放和细胞存活率的增加明显大于活性PKCβII水平高的CLL患者。此外,通过用PKCβ特异性抑制剂LY379196预处理细胞,活性PKCβII水平高的CLL患者中BCR诱导的Ca2+通量可以恢复。相反,通过用PKC激动剂苔藓抑素预处理,活性PKCβII水平低的CLL细胞中BCR介导的细胞内Ca2+释放可以被抑制。综上所述,这些结果表明,过表达的活性PKCβII在BCR信号的调节和结果中起作用,这可能对CLL的进展很重要。

相似文献

1
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII.慢性淋巴细胞白血病细胞中的B细胞受体信号传导由过度表达的活性蛋白激酶CβII调节。
Blood. 2007 Feb 1;109(3):1193-201. doi: 10.1182/blood-2006-03-012021. Epub 2006 Sep 26.
2
Vascular endothelial growth factor stimulates protein kinase CbetaII expression in chronic lymphocytic leukemia cells.血管内皮生长因子刺激慢性淋巴细胞白血病细胞中蛋白激酶 CβII 的表达。
Blood. 2010 Jun 3;115(22):4447-54. doi: 10.1182/blood-2009-06-229872. Epub 2010 Feb 17.
3
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.B细胞抗原受体信号传导增强慢性淋巴细胞白血病细胞的迁移和存活:用新型脾酪氨酸激酶抑制剂R406进行特异性靶向治疗。
Blood. 2009 Jul 30;114(5):1029-37. doi: 10.1182/blood-2009-03-212837. Epub 2009 Jun 2.
4
Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.苔藓抑素可诱导蛋白激酶C调节、Mcl-1上调以及Bcl-2磷酸化,从而导致B细胞慢性淋巴细胞白血病细胞发生细胞分化并产生对药物诱导凋亡的抗性。
Leuk Lymphoma. 2004 May;45(5):997-1008. doi: 10.1080/10428190310001639470.
5
Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.B细胞慢性淋巴细胞白血病中通过B细胞抗原受体激活细胞外信号调节激酶
Int J Hematol. 2002 Jun;75(5):508-13. doi: 10.1007/BF02982115.
6
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.蛋白激酶C-β作为慢性淋巴细胞白血病的治疗靶点:蛋白激酶C抑制剂AEB071在慢性淋巴细胞白血病中显示出临床前活性。
Blood. 2014 Aug 28;124(9):1481-91. doi: 10.1182/blood-2014-05-574830. Epub 2014 Jul 7.
7
BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.慢性淋巴细胞白血病中的 BCR 信号转导及目前处于临床研究阶段的相关抑制剂。
Int Rev Immunol. 2013 Aug;32(4):358-76. doi: 10.3109/08830185.2013.786711. Epub 2013 Apr 25.
8
LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.LCK 是慢性淋巴细胞白血病细胞中 B 细胞受体信号的重要介质。
Mol Cancer Res. 2013 May;11(5):541-54. doi: 10.1158/1541-7786.MCR-12-0415-T. Epub 2013 Mar 15.
9
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.通过B细胞受体的持续信号传导诱导Mcl-1并促进慢性淋巴细胞白血病B细胞的存活。
Blood. 2005 Jun 15;105(12):4820-7. doi: 10.1182/blood-2004-07-2669. Epub 2005 Feb 22.
10
Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression.对B细胞受体连接的存活反应仅限于进行性慢性淋巴细胞白血病细胞,而与Zap70表达无关。
Cancer Res. 2006 Jul 15;66(14):7158-66. doi: 10.1158/0008-5472.CAN-06-0085.

引用本文的文献

1
The function of serine/threonine-specific protein kinases in B cells.丝氨酸/苏氨酸特异性蛋白激酶在 B 细胞中的功能。
Front Immunol. 2024 Oct 9;15:1459527. doi: 10.3389/fimmu.2024.1459527. eCollection 2024.
2
DNA Methylation Analysis Reveals Potential Mechanism in Takifugu rubripes Against Cryptocaryon irritans Infection.DNA 甲基化分析揭示了红斑马鱼抵御刺激隐核虫感染的潜在机制。
Mar Biotechnol (NY). 2024 Apr;26(2):288-305. doi: 10.1007/s10126-024-10296-x. Epub 2024 Mar 6.
3
PKCβ Facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by Promoting Constitutive BCR-Mediated Signalling.
蛋白激酶Cβ通过促进组成型BCR介导的信号传导促进慢性淋巴细胞白血病的白血病发生。
Cancers (Basel). 2022 Dec 6;14(23):6006. doi: 10.3390/cancers14236006.
4
Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.血液癌症中失调的钙信号传导:潜在机制与治疗潜力
Front Oncol. 2022 Oct 18;12:1010506. doi: 10.3389/fonc.2022.1010506. eCollection 2022.
5
Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia.慢性淋巴细胞白血病的治疗方法与耐药性
Cancer Drug Resist. 2020 May 11;3(3):532-549. doi: 10.20517/cdr.2019.111. eCollection 2020.
6
The complexities of PKCα signaling in cancer.PKCα 信号在癌症中的复杂性。
Adv Biol Regul. 2021 May;80:100769. doi: 10.1016/j.jbior.2020.100769. Epub 2020 Nov 23.
7
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.针对癌症中布鲁顿酪氨酸激酶的抑制剂:药物研发进展。
Leukemia. 2021 Feb;35(2):312-332. doi: 10.1038/s41375-020-01072-6. Epub 2020 Oct 29.
8
A novel transgenic mouse strain expressing PKCβII demonstrates expansion of B1 and marginal zone B cell populations.一种新型表达 PKCβII 的转基因小鼠品系可扩增 B1 和边缘区 B 细胞群体。
Sci Rep. 2020 Aug 4;10(1):13156. doi: 10.1038/s41598-020-70191-y.
9
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies.B细胞受体激活机制及B细胞恶性肿瘤对B细胞受体抑制剂的反应
Cancers (Basel). 2020 May 28;12(6):1396. doi: 10.3390/cancers12061396.
10
Dual Targeting of Stromal Cell Support and Leukemic Cell Growth by a Peptidic PKC Inhibitor Shows Effectiveness against B-ALL.靶向细胞支持和白血病细胞生长的肽类 PKC 抑制剂对 B-ALL 有效。
Int J Mol Sci. 2020 May 25;21(10):3705. doi: 10.3390/ijms21103705.